<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00233909</url>
  </required_header>
  <id_info>
    <org_study_id>KAN-979-02</org_study_id>
    <nct_id>NCT00233909</nct_id>
  </id_info>
  <brief_title>A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia</brief_title>
  <official_title>An Open-Label, Phase I/II Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanisa Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanisa Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing
      or die. Zosuquidar may help Gemtuzumab Ozogamicin (GO) kill more cancer cells by making
      cancer cells more sensitive to the drug. It is not known whether Gemtuzumab Ozogamicin (GO)
      is more effective with or without zosuquidar in treating acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      Phase I: Determine the optimal dose and schedule of GO and zosuquidar when used in
      combination.

      Phase II: Determine the complete remission rate (CR+CRp)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Leukemia, Myeloid</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zosuquidar</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Morphologic evidence of acute myeloid leukemia in first relapse.

          2. Phase I: 18 years or older, Phase II: 50 years or older

        Exclusion Criteria:

          1. Prior treatment with zosuquidar

          2. Any investigational agent within 1 month of enrollment and lack of recovery from
             toxicities secondary to those agents

          3. History of stem cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <last_update_submitted>March 28, 2008</last_update_submitted>
  <last_update_submitted_qc>March 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <keyword>Leukemia, Myeloid</keyword>
  <keyword>Relapse</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Zosuquidar</keyword>
  <keyword>gemtuzumab ozogamicin (GO)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

